Concomitant 20.9 Antiplatelets: 7.6 NR Non-ASA antiplatelets:* Antiplatelets: antiplatelets/NSAIDs, % NSAIDs: 10.2 10.3 23.7 ASA:* 40.2 NSAIDs: NSAIDs:14.2 36.9 Impaired renal function, % CrCl <50 mL/min: CrCl <50 mL/min: 11.5 12.5 Abnormal renal Renal disease: >15 Renal disease: 4.1 Renal function: 6.9† insufficiency: 17.1 Patient risk scores CHADS2 mean 2.0 2.4 NR NR NR CHA2DS2-VASc score, 3.5 NR NR 3.0 3.7 mean CHA2DS2-VASc % 87.9 92.6 90.7 81.7 NR ≥2,
Concomitant antiplatelets/NSAIDs, % 20.9 Antiplatelets: 7.6 NSAIDs: 10.2 NR Non-ASA antiplatelets:* 10.3 ASA:* 40.2 NSAIDs:14.2 Antiplatelets: 23.7 NSAIDs: 36.9 Impaired renal function, % CrCl <50 mL/min: 11.5 Abnormal renal function: 6.9† CrCl <50 mL/min: 12.5 Renal disease: >15 Renal disease: 4.1 Renal insufficiency: 17.1 Patient risk scores CHADS2 mean 2.0 2.4 NR NR NR CHA2DS2-VASc score, mean 3.5 NR NR 3.0 3.7 CHA2DS2-VASc ≥2, % 87.9 92.6 90.7 81.7 NR
1-s2.0-S0735109718347958-mmc1.docx